Hi paolo,
I am pleased you like the ME/CFS roadmap.
It would great if you write a similar document in Italian. I think there is a strong need to make patients aware of the medical treatments that are available for ME/CFS, because in so many countries (particularly the UK), ME/CFS is still often considered a psychogenic disease, so that patients are then given inappropriate psychological treatments, such as cognitive behavioral therapy (CBT), rather than treatments that address the underlying biology of the disease.
You may be interested in these documents if you are writing an Italian ME/CFS treatment guide:
ME/CFS Treatment Resource Guide for Practitioners, A. Martin Lerner
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Diagnosis and Management: The Basics and Beyond, Daniel Peterson
It seems to me that you did not consider some envariomental factors such as heavy metals exposure.
I did consider heavy metals, but I could find no evidence that heavy metals such as mercury are linked to ME/CFS. There are no studies showing higher levels of mercury in ME/CFS, nor are there any studies showing that chelation improves ME/CFS. And I have not seen any good anecdotal reports of chelation improving ME/CFS (but if you know of any evidence, please let me know).
The idea is to only include treatments in the roadmap that are known to help ME/CFS. I don't want to send ME/CFS patients on a wild goose chase (ie, pursuit of something that will not be helpful). If any patient wants to experiment with chelation or mercury dental amalgams removal themselves, that's fine, but there is no evidence I know of that suggests this will help. I had my mercury dental amalgams removed purely as a precaution; however, I wouldn't want to say in the roadmap that is a recommended path of action.
I have included all the environmental risk factors for developing ME/CFS I could find. The main one seems to be significant pesticide exposure (such as found in farmers using "sheep dip" organophosphate treatment for sheep), which some studies found increases the risk of ME/CFS by 4 times. Mold exposure is also linked to increased ME/CFS risk, but there is less evidence for this.
Some ME/CFS doctors suggested that tung oil exposure is a risk factor for ME/CFS, so that is included in the roadmap.
I would like to ask why you (as well as J Montoya) consider a borrelia infection to be something else from CFS, while you consider HHV6 as a manifestation of CFS/ME. I would say that if chronic borrelia is not CFS, then chronic HHV6 is not CFS as well.
...
Your description of chronic Lyme is CDC oriented, but that is only one possible way to describe this illness. I would suggest you to consider also the descriptions of other authors, as S Donta and B Fallon, and you will find that chronic Lyme has the same identical features of CFS, in many cases, without joints swelling, for istance.
Discussion on the great similarity between Lyme and ME/CFS sometimes takes place on this forum, and some people suggest that ME/CFS and Lyme are the same disease.
Certainly I would think that whatever the mechanism is in ME/CFS that leads to brain fog and fatigue, this same mechanism may be present in Lyme disease too. And likely present in other fatiguing conditions such as chronic hepatitis C virus infection.
However, there are certain symptoms of Lyme that you do not find in ME/CFS. For example, Bell's palsy can occur in Lyme, but not normally in ME/CFS. Arthritis can occur in Lyme, particularly in the knees, whereas in ME/CFS, if there are joint pains, they are
arthralgia rather than
arthritis. And in ME/CFS the arthralgia will often migrate from one joint to another.
It is also not entirely clear whether Lyme patients suffer from post-exertional malaise (PEM), though some say they do. PEM is a mandatory symptom in the stricter definitions of ME/CFS such as the CCC or ICC definitions.
And there may be differences in NK function: in Lyme patients, I have seen some reports of low
numbers of NK cells; whereas in ME/CFS the number of NK cells is normal, but their
activation is low.
I am not against the idea that Lyme might one day be classified as a form of ME/CFS, but at present few medical authorities view it like this, so the roadmap just reflects this.
Moreover testing with double tiers procedure (Elisa + western blot) is not as reliable as you say. This is well known and documented. Many Lyme patients have negative sierology, and still have positive PCR. You can easly find pubblications on this topic in Pub Med.
The CDC test for Lyme is a more conservative one (less sensitivity, more specificity †): if you test positive, then you have Lyme to a good degree of certainty. Such conservative testing is important in say research studies, where you want to make sure that all your cohort do indeed have Lyme disease.
Other Lyme tests can be more "speculative" (more sensitivity, less specificity †): if you test positive, you might well have Lyme, but there also is a good chance you may not. These more speculative tests might useful for patients who don't mind the possibility that a positive result may be wrong, and on testing positive will go ahead and try some of the Lyme treatments anyway, and see if they help or not. Which can be a good idea.
I have heard stories of patients that were Lyme negative by the CDC test, but positive by other more speculative tests, and then gained benefit from Lyme treatments. So there is definitely a good argument for using one of the more speculative tests if you are an individual patient.
However, the roadmap does not really cover the intricacies of Lyme testing. I am an ME/CFS patient, not a Lyme patient, so unfortunately I don't really know that much about Lyme (I live in a part of the UK where there is a very low Lyme risk, and my ME/CFS was clearly precipitated by a viral infection which started as a sore throat). It's often only when you have first hand experience with a disease like Lyme, ME/CFS or fibromyalgia that you really understand it. Was only able to create this roadmap because of all my reading about tests and treatments for ME/CFS.
† Sensitivity is the proportion of people with the disease who have a positive test result. Specificity is the proportion of people without the disease who have a negative test result.